体外研究 (In Vitro) |
Curdione (12.5-50 μM, 48 小时) 可降低 CT26 细胞活力,促进细胞内 ROS 生成,增加 METTL14 和 YTHDF2 的表达水平,并降低 SLC7A11、SLC3A2、HOXA13 和 GPX4 的表达水平。
Curdione (12.5-50 μM, 48 小时) 可降低 CT26 和 SW480 细胞中的 GSH 浓度,增加 MDA、m6A、亚铁和 LPO 水平,并增加 SLC7A11 和 HOXA13 的 mRNA 水平。
Curdione (50 μM, 48 小时) 在 shRNA-METTL14 CT26 和 SW480 细胞中可降低细胞 ROS 浓度、Fe2+ 和 MDA 水平,增加 GSH 活性,并通过 m6A 修饰诱导铁死亡 XC 系统和的甲基化转移酶METTL14。
Curdione (12.5-50 μM,48 小时) 在 SW480 细胞中诱导细胞凋亡,其凋亡抑制剂 (Z-VAD-FMK (MS-L66221)) 对铁死亡无影响。
Curdione (25-100 μM,24 小时) 可提高 Isoproterenol (ISO) (MS-H12927) 诱导的 H9c2 细胞的存活率,减轻 Erastin (MS-C46386) 诱导的 H9c2 细胞的细胞损伤。
Curdione (25-100 μM,24 小时) 与 Keap1 结合,调节 H9c2 细胞中的 Keap1/Trx1/GPX4 信号通路。
Curdione (100-200 μM) 可抑制小鼠骨髓中分离的中性粒细胞在接受 Phorbol 12-myristate 13-acetate (PMA) (MS-C34076) 或化脓性血小板刺激后形成中性粒细胞胞外陷阱 (NET)。。
Curdione (160-500 μM,48 小时) 不影响细胞活力,抑制成纤维细胞分化为肌成纤维细胞,并抑制 HPF 中的 TGF-β/Smad3 信号传导。
Curdione (0-500 μM,12-72 小时) 在 SK-UT-1 和 SK-LMS-1 细胞中可降低细胞活力,抑制抑制 IDO1 介导的增殖,IC50 分别为 327 和 309.9 μM。
Curdione (0-100 μM,24 小时) 诱导 SK-UT-1 和 SK-LMS-1 细胞中 IDO1 介导的 G2/M 期停滞、细胞凋亡和自噬。
Curdione (0-200 μg/mL,72 小时) 诱导细胞凋亡,损害 MCF-7 细胞中的线粒体膜电位 (IC50 = 125.632 μg/mL)。
Western Blot Analysis
| Cell Line: |
CT26 cells |
| Concentration: |
12.5 μM, 25 μM, 50 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the expression levels of METTL14 and YTHDF2, and decreased the expression levels of SLC7A11, SLC3A2, HOXA13, and GPX4. |
Western Blot Analysis
| Cell Line: |
shRNA-METTL14 CT26 and SW480 cells |
| Concentration: |
50 μM |
| Incubation Time: |
48 h |
| Result: |
Increased expression of SLC7A11, HOXA13, SLC3A2 and GPX4. |
Apoptosis Analysis
| Cell Line: |
SW480 cells |
| Concentration: |
12.5 μM, 25 μM, 50 μM |
| Incubation Time: |
48 h |
| Result: |
Inducted apoptosis, promoted the development of ferroptosis.
Had no statistically significant difference of ferroptosis when combined with Z-VAD-FMK (MS-L66221) (10 μM).
|
Western Blot Analysis
| Cell Line: |
H9c2 cells |
| Concentration: |
100 μmol/L |
| Incubation Time: |
1 h |
| Result: |
Increased the stability of Keap1. |
Western Blot Analysis
| Cell Line: |
H9c2 cells/ Flag-Keap1, HA-GPX4, and Myc-Trx1 plasmids and tranfected to 293T cells |
| Concentration: |
25 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Inhibited Keap1 expression and increased ISO-induced Trx1 expression, reduced interaction between Keap1 and Trx1 and increased complex between Trx1 and GPX4. |
Western Blot Analysis
| Cell Line: |
HPFs |
| Concentration: |
160 μM, 300 μM |
| Incubation Time: |
48 h |
| Result: |
Reduced fibronectin, collagen 1, and α-SMA levels.
Attenuated TGF-β1-induced p-Smad3 activation, but not p-Smad2.
|
RT-PCR
| Cell Line: |
HPFs |
| Concentration: |
160 μM, 300 μM |
| Incubation Time: |
48 h |
| Result: |
Reduced fibronectin, collagen 1, and α-SMA levels, increased Smad7 inhibits p-Smad3 |
Immunofluorescence
| Cell Line: |
HPFs |
| Concentration: |
160 μM, 300 μM |
| Incubation Time: |
48 h |
| Result: |
Reduced fibronectin, collagen 1, and α-SMA levels. |
Immunofluorescence
| Cell Line: |
SK-UT-1 and SK-LMS-1 cells |
| Concentration: |
0 μM, 25 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the expression of EdU and Ki67. |
Cell Cycle Analysis
| Cell Line: |
SK-UT-1 and SK-LMS-1 cells |
| Concentration: |
0 μM, 25 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Induced G2/M phase arrest. |
Western Blot Analysis
| Cell Line: |
SK-UT-1 and SK-LMS-1 cells |
| Concentration: |
0 μM, 25 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Up-regulated the cell cycle checkpoint proteins P21 and CyclinB1 and down-regulated Cdc2.
Increased cleavage of caspase 3, 6, and 9 without affecting caspase 8.
Up-regulateed LC3 and Beclin-1, and down-regulated P62, IDO1.
|
Apoptosis Analysis
| Cell Line: |
SK-UT-1 and SK-LMS-1 cells |
| Concentration: |
0 μM, 25 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Increased the percentage of early and late apoptotic cells and induced cell death. |
Apoptosis Analysis
| Cell Line: |
MCF-7 cells |
| Concentration: |
0, 25, 50, 100, 150, 200 μg/mL | ...(内容过长已截断)
体内研究 (In Vivo) |
Curdione (50-200 mg/kg,静脉注射,每日一次,22 天) 在 CRC 异种移植裸鼠中可抑制肿瘤生长,并通过 METTL14 和 YTHDF2 诱导由 m6A 甲基化介导的铁死亡。
Curdione (25-100 mg/kg,灌胃,每日一次,共 7 天) 在 ISO 诱导的心肌梗死 (MI) 雄性小鼠模型中可减轻心肌损伤,并通过调节 Keap1/Trx1/GPX4 信号通路缓解铁死亡。
Curdione (50-100 mg/kg,腹腔注射,一次) 在盲肠结扎穿刺 (CLP) 脓毒症小鼠模型中可改善肺损伤,降低炎症和氧化应激水平,抑制 MAPK 激酶和 NF-κB P65 的激活,肺中性粒细胞浸润和 NET 形成,调节血小板活化,并减少中性粒细胞与血小板的相互作用。
Curdione (100 mg/kg,腹腔注射,每 2 天一次,共 21 天) 在 Bleomycin (BLM) (MS-K75594) 诱导的特发性肺纤维化 (IPF) 小鼠模型中可减轻肺纤维化,降低纤维化特异性标志物的表达,并抑制成纤维细胞分化为肌成纤维细胞。
Curdione (100 mg/kg,腹腔注射,每天一次,共 7 天) 在动脉闭塞 (MCAO) SD 大鼠模型中通过抗氧化和抗凋亡作用,对脑缺血/再灌注引起的脑损伤发挥神经保护作用。
Curdione (100-200 mg/kg,腹腔注射,每日一次,共 21 天) 通过靶向 IDO1 并激活细胞凋亡和自噬来抑制 SK-UT-1 异种移植模型中的 uLMS 生长
Curdione (50-150 mg/kg,每两天一次,共 16 天) 可抑制 MCE-7 异种移植 BALB/c 裸鼠模型中的肿瘤生长
| Animal Model: |
CRC (0.5 × 107, CT26 cells) xenograft nude mice |
| Dosage: |
50 mg/kg, 100 mg/kg, 200 mg/kg |
| Administration: |
i.v., once a day, 22 days |
| Result: |
Suppressed tumor volume and mass, exhibited pronounced ruffling and nuclear chromatin boundary setting, accompanied by necrosis and fibrosis, and decreased cell density.
Increased iron, MDA, and LPO levels, and decreased GSH levels.
Increased protein expression of METTL14, YTHDF2, SLC7A11, and decreased protein expression levels of SLC3A2, HOXA13, and GPX4.
Increased mRNA expression of YTHDF2, SLC7A11, SLC3A2, HOXA13, and PTGS2 and decreased mRNA expression of GPX4.
|
| Animal Model: |
ISO (100 mg/kg)-induced MI C57BL/6 mice (21-25 g, 6-8 weeks) model |
| Dosage: |
25 mg/kg, 50 mg/kg, 100 mg/kg |
| Administration: |
i.g., once a day, 7 days |
| Result: |
Improved ejection fraction (EF), reduced ISO-increased CK-MB levels, restored normal muscle fiber structure, and reduced the degree of inflammatory cell infiltration in cardiac tissue.
Lowered MDA and iron levels and increaseed GSH, GPX4, FTH1 levels.
Inhibited Keap1 expression and increased ISO-induced Trx1 expression.
|
| Animal Model: |
CLP sepsis mice (8-10 weeks old, Male) model |
| Dosage: |
50 mg/kg, 100 mg/kg |
| Administration: |
i.p., once |
| Result: |
Reduced lung congestion, alveolar wall thickening, and inflammatory cell infiltration in lung sections, reduced lung injury scores, pulmonary edema, and reduced exudate protein levels in BALF and lung W/D ratio, as well as LDH activity in BALF.
Reduced CLP-induced increases in DHE and MDA, increased superoxide dismutase (SOD) levels, and decreased IL-1β, IL-6, and TNF-α levels in BALF.
Inhibited the phosphorylation of MAPK kinase and NF-κB P65, and reduced the activation of NF-κB P65.
Reduced CXCL4 and CXCL7 in BALF and reduced platelet activation in lung tissue.
Decreased MPO-positive neutrophils, total cell counts in BALF, and the number of infiltrating neutrophils in BALF.
Reduced fluorescence intensity of platelet activation markers CD42d/GP5, neutrophil marker Ly6G and the formation of NETs in the lungs.
|
| Animal Model: |
BLM-induced IPF mouse (8 weeks old, male) model |
| Dosage: |
100 mg/kg |
| Administration: |
i.p., every 2 days, 21 days |
| Result: |
Reduced lung injury, lung fibrosis, and inflammatory cell (lymphocyte and macrophage) infiltration levels, reduced hydroxyproline content.
Reduced protein and mRNA expression levels of fibronectin, collagen 1, and α-SMA.
Reduced α-SMA positive cells and reduced fibroblast differentiation.
|
| Animal Model: |
MCAO SD rats (240-270 g, adult male) model |
| Dosage: |
100 mg/kg |
| Administration: |
i.g., once a day, 7 days |
| Result: |
Reduced infarct size and neurological deficits and promoted motor function and cognitive function recovery.
Reversed the obvious pathological abnormalities of the MCAO group, including loose arrangement of neurons, nuclear consolidation, loss of color staining or dark color.
Increased the activities of SOD, CAT and GSH-PX, suppressed the increase in the MDA content caused by the injury with cerebral ischemia/reperfusion.
Down-regulated Bax expression and up-regulated Bcl-2 expression, thereby increasing the Bcl-2/Bax ratio, reduced Cyt-C, c-caspase-3, and c-caspase-9 protein levels.
|
| Animal Model: |
SK-UT-1 (1 × 107) xenograft BALB/c nude mice (6-7 weeks, female, 18 g) model |
| Dosage: |
100 mg/kg, 200 mg/kg |
| Administration: |
i.p., once a day, 21 days |
| Result: |
Exhibited anti-uLMS growth efficacy with minimal systemic toxicity, down-regulated IDO1, ki67, and p62, and up-regulated the cleaved caspase-3, Beclin1 and LC3 in tumor tissues. |
| Animal Model: |
MCE-7 (1 × 107) xenograft BALB/c nude mice (5-6 weeks, female, 20 g) model |
| Dosage: |
50 mg/kg, 100 mg/kg, 150 mg/kg |
| Administration: |
every two days, 16 days |
| Result: |
Inhibited tumor growth. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
236.35 |
| 分子式 |
C15H24O2 |
| CAS No. |
13657-68-6 |
| 别名 |
莪术二酮; (+)-Curdione |
| 体内实验配方 |
10% DMSO+90% Saline: 10 mg/mL (42.31 mM), Suspension. ![]() 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.46 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
2 years |
|
-20°C |
1 year |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 100 mg/mL (423.10 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 4.2310 mL | 21.1551 mL | 42.3101 mL | 105.7753 mL | | 5 mM | 0.8462 mL | 4.2310 mL | 8.4620 mL | 21.1551 mL | | 10 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL | 10.5775 mL | | 15 mM | 0.2821 mL | 1.4103 mL | 2.8207 mL | 7.0517 mL | | 20 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL | 5.2888 mL | | 25 mM | 0.1692 mL | 0.8462 mL | 1.6924 mL | 4.2310 mL | | 30 mM | 0.1410 mL | 0.7052 mL | 1.4103 mL | 3.5258 mL | | 40 mM | 0.1058 mL | 0.5289 mL | 1.0578 mL | 2.6444 mL | | 50 mM | 0.0846 mL | 0.4231 mL | 0.8462 mL | 2.1155 mL | | 60 mM | 0.0705 mL | 0.3526 mL | 0.7052 mL | 1.7629 mL | | 80 mM | 0.0529 mL | 0.2644 mL | 0.5289 mL | 1.3222 mL | | 100 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 1.0578 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|